Valuation: Insmed Incorporated

Market Cap 22.7B 19.96B 18.58B 17.06B 32.03B 2,177B 32.46B 221B 86.24B 1,075B 85.22B 83.38B 3,715B P/E 2026 *
-41x
P/E 2027 * 208x
Enterprise Value 22.14B 19.46B 18.12B 16.64B 31.24B 2,123B 31.65B 215B 84.1B 1,048B 83.1B 81.31B 3,623B EV / Sales 2026 *
13x
EV / Sales 2027 * 7.82x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Insmed Incorporated

1 day-2.05%
1 week-2.14%
Current month-1.77%
1 month+1.31%
3 months-22.98%
6 months-35.61%
Current year-39.82%
1 week 104.5
Extreme 104.5
109.99
1 month 103.08
Extreme 103.08
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.94
Extreme 20.94
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
Change 5-day change 1-year change 3-year change Capi.($)
-2.05%-2.14%+0.75%+413.38% 22.7B
-0.94%+2.95%+52.91%+72.38% 56.19B
-0.27%+0.35%+40.26%+79.88% 54.83B
+1.97%-1.16%-21.00%-13.25% 23.04B
-0.21%-0.62%+20.56%-10.90% 20.23B
-1.06%+1.81%+25.94%-30.33% 17.83B
-0.97%-0.59%+33.12%+550.67% 15.65B
+5.29%+1.70%+185.09%+333.94% 15.24B
+0.79%+0.50%+22.39%+184.74% 14.03B
+1.24%+2.90%+84.74%+175.74% 12.71B
Average +0.38%+0.63%+44.47%+175.63% 25.24B
Weighted average by Cap. +0.01%+0.94%+40.89%+139.82%

Financials

2026 *2027 *
Net sales 1.7B 1.5B 1.39B 1.28B 2.4B 163B 2.43B 16.54B 6.46B 80.54B 6.38B 6.25B 278B 2.78B 2.44B 2.27B 2.09B 3.92B 266B 3.97B 27.01B 10.55B 131B 10.42B 10.2B 454B
Net income -561M -493M -459M -422M -792M -53.83B -803M -5.46B -2.13B -26.58B -2.11B -2.06B -91.87B 71.64M 62.98M 58.62M 53.84M 101M 6.87B 102M 697M 272M 3.39B 269M 263M 11.72B
Net Debt -563M -495M -461M -423M -795M -54B -805M -5.48B -2.14B -26.66B -2.11B -2.07B -92.16B -979M -860M -801M -735M -1.38B -93.84B -1.4B -9.52B -3.72B -46.34B -3.67B -3.59B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-27 US$104.73 -2.05% 1,899,713
26-07-24 US$106.92 -0.46% 1,908,298
26-07-23 US$107.41 +0.72% 1,752,962
26-07-22 US$106.64 -1.82% 1,771,277
26-07-21 US$108.62 +1.50% 2,447,392
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
104.73USD
Average target price
196.18USD
Spread / Average Target
+87.32%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock